Table 3.

Secondary endpoint: 28-day survival rate

AT activity (%)	Survival
	pAT	AT gamma
	% (n/N)	% (n/N)
< 50	76.7 (33/43)	85.4 (35/41)
50–70	78.3 (54/69)	89.7 (61/68)
Total [95% CI]	77.7 (87/112) [68.8–85.0]	87.3 (96/110) [79.6–92.9]
Adjusted a [95% CI]	77.7 [70.7–84.7]	88.1 [81.1–95.0]

AT antithrombin, CI confidence interval, pAT plasma-derived antithrombin

^aThe protocol was amended to include all patients with AT activity ≤ 70% so that the patient population would more accurately reflect the intended clinical use. The (adjusted) survival rate and its 95% CI were calculated for each treatment group after stratification using the Woolson–Bean method, stratified by the AT activity (< 50%, 50–70%) at study enrollment